Evidence map›Paper›PMID 37313819›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2023

[Therapeutic mechanism of

Y Zhao, X Zhao, Q Zhu, B Zhu, Z Zhang, J Chen

Open access · greenAbstract readEnglish Abstract
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Y ZhaoSecond Clinical Medical College, Dalian Medical University, Dalian 116044, China.
X ZhaoInstitute (College) of Integrative Medicine, Dalian Medical University, Dalian 116044, China.
Q ZhuInstitute (College) of Integrative Medicine, Dalian Medical University, Dalian 116044, China.
B ZhuSecond Clinical Medical College, Dalian Medical University, Dalian 116044, China.
Z ZhangSecond Clinical Medical College, Dalian Medical University, Dalian 116044, China.
J ChenInstitute (College) of Integrative Medicine, Dalian Medical University, Dalian 116044, China.
Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo predict the targets and pathways in the therapeutic mechanism of

methodsThe chemical components of GZGCD were analyzed using the databases including TCMSP, TCMID and TCM@Taiwan, and the potential targets of GZGCD were predicted using the SwissTargetPrediction database. The targets of HF were obtained using the databases including DisGeNET, Drugbank and TTD. The intersection targets of GZGCD and HF were identified using VENNY. Uniport database was used to convert the information, and the components-targets-disease network was constructed using Cytoscape software. The Bisogene plug-in, Merge plug-in, and CytoNCA plug-in in Cytoscape software were used for protein-protein interaction (PPI) analysis to acquire the core targets. Metascape database was used for GO and KEGG analysis. The results of network pharmacology analysis were verified with Western blot analysis. Three factors (PKC

resultsWe identified a total of 190 intersection targets between GZGCD and HF using Venny database, involving mainly the circulatory system process, cellular response to nitrogen compounds, cation homeostasis, and regulation of the MAPK cascade. These potential targets were also involved in 38 pathways, including the regulatory pathways in cancer, calcium signal pathway, cGMP-PKG signal pathway, and cAMP signal pathway. Western blot analysis showed that in an

conclusionThe therapeutic mechanism of GZGCD for HF involves multiple targets including PRKCA, PRKCB, MAPK1, MAPK3, and MAPK8 and multiple pathways including the regulatory pathway in cancer and the calcium signaling pathway.

Indexed as

Heart FailureProtein Kinase C-alphaDrugs, Chinese HerbalGlycyrrhizaHumansNetwork PharmacologyProto-Oncogene Proteins c-bcl-2Drugs, Chinese Herbalglycyrrhizae radix et rhizomaProtein Kinase C-alphaProto-Oncogene Proteins c-bcl-2Guizhi Gancao Decoctionheart failuremolecular mechanismnetwork pharmacology

Identifiers

PMID37313819
PMCPMC10267239
OpenAlexW4380576356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.